# Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

> **NCT00266630** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 139 (actual)

## Conditions studied

- Manic or Mixed Episode Associated With Bipolar I Disorder

## Interventions

- **DRUG:** olanzapine
- **DRUG:** lithium
- **DRUG:** valproate
- **DRUG:** carbamazepine

## Key facts

- **NCT ID:** NCT00266630
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2010-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266630, "Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00266630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*